TY  - JOUR
AU  - Aragoneses-Fenoll, Laura
AU  - Ojeda, Gloria
AU  - Montes-Casado, Maria
AU  - Acosta-Ampudia, Yeny
AU  - Dianzani, Umberto
AU  - Portoles, Pilar
AU  - Rojo, José M
PY  - 2018
DO  - 10.3389/fimmu.2018.00332
SN  - 1664-3224
UR  - http://hdl.handle.net/20.500.12105/8959
AB  - Class IA phosphatidylinositol 3-kinase (PI3K) catalytic subunits p110α and p110δ are targets in cancer therapy expressed at high levels in T lymphocytes. The role of p110δ PI3K in normal or pathological immune responses is well established, yet the...
LA  - eng
PB  - Frontiers Media
KW  - CD28 costimulation
KW  - PI3-kinase alpha subunit
KW  - PI3K
KW  - T lymphocytes
KW  - Anti-KLH response
KW  - Melanoma
KW  - Animals
KW  - CD8-Positive T-Lymphocytes
KW  - Class I Phosphatidylinositol 3-Kinases
KW  - Extracellular Signal-Regulated MAP Kinases
KW  - Interferon-gamma
KW  - MAP Kinase Signaling System
KW  - Mice
KW  - Mice, Knockout
KW  - Neoplasms, Experimental
KW  - Proto-Oncogene Proteins c-akt
KW  - T-Lymphocytes, Regulatory
KW  - Immunity, Cellular
TI  - T-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response
TY  - journal article
ER  -